What We're Reading: Page 223
Industry reads hand-picked by our editors
Apr 10, 2019
Apr 09, 2019
-
The New York Times
The Diagnosis Is Alzheimer’s. But That’s Probably Not the Only Problem.
-
Bloomberg
Drug Middlemen Face State Probes Over 'Complex' Pricing System
-
Slate
When you die, where should we upload your brain?
-
Buzzfeed
Republicans Jim Jordan And Mark Meadows Warn Drug Companies Not To Cooperate With Congressional Investigation
Apr 08, 2019
-
The Wall Street Journal
Botox Rivals Create New Wrinkles for Allergan
-
The New York Times
In a Poor Kenyan Community, Cheap Antibiotics Fuel Deadly Drug-Resistant Infections
-
BioCentury
Big caps under pressure
-
Bloomberg
Gene Therapy Was Hailed as a Revolution. Then Came the Bill.
Apr 05, 2019
Apr 04, 2019
-
Bloomberg
Novartis CEO's $50 Billion of Deals Was Just the First Act
-
The Washington Post
FDA’s Gottlieb heads back to AEI to tackle drug prices
-
Financial Times
Some drug companies are still imposing triple-digit price rises
-
BioCentury
FDA's Pazdur encourages Chinese companies to bring low-cost PD-1 drugs to U.S. market
Apr 03, 2019
-
The New York Times
One Day There May Be a Drug to Turbocharge the Brain. Who Should Get It?
-
The Wall Street Journal
Generic-Drug Trends Squeeze Walgreens Profit
-
Healthcare Dive
Hospitals look to venture capital as R&D extension
-
California Healthline
Finding Homeless Patients A Place To Heal
Apr 02, 2019
-
Forbes
Sources: Martin Shkreli Thrown In Solitary Confinement After Claims He Ran Company From Prison
-
BioCentury
Pazdur grills PD-1/PD-L1 companies over lack of collaboration, trial redundancies
-
Kaiser Health News
Elite hospitals plunge into unproven stem cell treatments
-
STAT
Biotech's biggest companies open their labs to an unlikely inspector: a vet
Previous
